HPV vaccine rollout reaches 8 million doses in India
The health ministry disclosed that the nation has now crossed the eight‑million mark for HPV immunisation. This achievement is described as a pivotal milestone in the fight against HPV infections that can lead to cervical, anal, throat cancers and genital warts. The vaccine offers long‑term protection by preventing the cellular changes that precede cancer. While the two‑dose regimen remains the standard for children aged 9‑14, a single‑dose strategy is being employed in specific settings. For youths and adults up to 45 years, a three‑dose catch‑up schedule is recommended, completed within six months. Safety data from global surveillance confirm the vaccine’s excellent profile, with only transient reactions such as soreness at the injection site, mild fever or headache.